Notably, en-T cells showed a significantly higher ratio of CD25-expressing cells in CTXpre/CD4post than in the CTXpre group, implying that anti-CD4 treatment heightened the tumor reactivity of CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.